APA (7th ed.) Citation

Perrotta, N., Coluccia, A., Rossi, F., Amato, G., & Polito, G. (2026). Pharmacoeconomic Analysis of Osimertinib Compared to Earlier‐Generation EGFR Inhibitors in EGFR‐Mutated NSCLC: A Systematic Review. Cancer Medicine, 15(7), 1. https://doi.org/10.1002/cam4.72129

Chicago Style (17th ed.) Citation

Perrotta, Nicola, Adriana Coluccia, Francesca Rossi, Giulia Amato, and Giacomo Polito. "Pharmacoeconomic Analysis of Osimertinib Compared to Earlier‐Generation EGFR Inhibitors in EGFR‐Mutated NSCLC: A Systematic Review." Cancer Medicine 15, no. 7 (2026): 1. https://doi.org/10.1002/cam4.72129.

MLA (9th ed.) Citation

Perrotta, Nicola, et al. "Pharmacoeconomic Analysis of Osimertinib Compared to Earlier‐Generation EGFR Inhibitors in EGFR‐Mutated NSCLC: A Systematic Review." Cancer Medicine, vol. 15, no. 7, 2026, p. 1, https://doi.org/10.1002/cam4.72129.